November 30, 2007 — /PRNewswire/ — HELSINGBORG, SWEDEN — NOLabs AB, the Swedish medtech company developing innovative nitric oxide-containing medical devices based on the NitroSense(R) technology, today reported that it has achieved another important milestone in the development of a new line of products for wounds infected by MRSA bacteria. MRSA stands for methicillin-resistant Staphylococcus aureus, a bacterium that is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.
In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs’ technology has a promising ability to kill a wide range of pathogens, including MRSA.
According to the U.S. Centers for Disease Control and Prevention, 126,000 hospitalisations are related to MRSA and 19,000 deaths are associated with serious MRSA infections every year in U.S. hospitals. Patients at risk for infection with MRSA include those with severe disease, recent surgery, or indwelling medical devices, such as urinary catheters.
Goran Beijer, CEO of NOLabs, says, “The recent results show that we are on the right track towards products with an enormous potential globally. The antimicrobial effect of NO will be key in several products that will prevent and/or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008.”
NOLabs’ NitroSense(R) technology assures controlled, local delivery of pure nitric oxide in a well defined concentration range during a well defined time period. The main areas are prevention of catheter-related urinary tract infections, relief of neuropathic pain, and wound care products with an antibacterial effect.
NOLabs is a Swedish medtech company developing and marketing nitric oxide-containing medical devices for various medical applications. Nitric oxide is a natural substance, produced by the human body. Its physiological effects include the control of local blood supply and the protection against microbes. In particular, NOLabs focuses on prevention of infection and pain relief for patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of catheter-associated urinary tract infections. NOLabs has developed the innovative, cost efficient and highly effective NitroSense(R) Technology with a significant potential to address serious health issues that impact the lives of over 100 million people.
Source: NOLabs AB